64. The logic, methodological and practical flaws of the harm-benefit-analysis in Directive 2010/63/EU

This publication has 13 references indexed in Scilit:

• White Paper and Colourful Language: Toward a Realistic View of Animal Research
  Alternatives to Laboratory Animals, 2017
• Recommendations for Addressing Harm–Benefit Analysis and Implementation in Ethical Evaluation – Report from the AALAS–FELASA Working Group on Harm–Benefit Analysis – Part 2
  Laboratory Animals, 2016
• Current concepts of Harm–Benefit Analysis of Animal Experiments – Report from the AALAS–FELASA Working Group on Harm–Benefit Analysis – Part 1
  Laboratory Animals, 2016
• The Heroes of CRISPR
  Cell, 2016
• From Scientific Discovery to Cures: Bright Stars within a Galaxy
  Cell, 2015
• Evaluating the ethical acceptability of animal research
  Lab Animal, 2014
• Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
  Pharmacoepidemiology and Drug Safety, 2011
• Study Affirms Pharma's Influence on Physicians
  JNCI: Journal of the National Cancer Institute, 2007
• Rare diseases and orphan drugs
  British Journal of Clinical Pharmacology, 2006
• Bromfenac(Duract)-Associated Hepatic Failure Requiring Liver Transplantation
  American Journal of Gastroenterology, 1999